In a recent announcement, the FDA shared, “If you’re bothered by bumps on your skin, don’t try to diagnose yourself or treat your condition with products that haven’t been approved by the [FDA]. Instead, visit a health care professional for a proper diagnosis.”
Now you and your healthcare provider have a new molluscum treatment option.
Ask your dermatologist for YCANTH.
In a recent announcement, the FDA shared, “If you’re bothered by bumps on your skin, don’t try to diagnose yourself or treat your condition with products that haven’t been approved by the [FDA]. Instead, visit a health care professional for a proper diagnosis.”
Now you and your healthcare provider have a new molluscum treatment option.
Ask your dermatologist for YCANTH.
In a recent announcement, the FDA shared, “If you’re bothered by bumps on your skin, don’t try to diagnose yourself or treat your condition with products that haven’t been approved by the [FDA]. Instead, visit a health care professional for a proper diagnosis.”
Now you and your healthcare provider have a new molluscum treatment option.
Ask your dermatologist for YCANTH.
YCANTH is a topical solution administered in office by a healthcare professional—often a dermatologist. No cutting or freezing is required.
Ask your dermatologist for YCANTH.
YCANTH is a compound with an active ingredient called "cantharidin," a blistering agent derived from a substance found in nature.* Although cantharidin has been used therapeutically for decades to treat other skin conditions, YCANTH is the first FDA-approved formulation of cantharidin.
*YCANTH should only be used on your skin. Talk to your healthcare provider about what to do after treatment. Please see Important Safety Information.
During your in-office visit, your healthcare provider will apply a small, targeted amount of YCANTH directly to each bump. YCANTH causes small blisters on your skin to help remove the virus. Blistering is expected, with 98% of lesions smaller than a dime. Because you can see blisters forming, you can see YCANTH working.
YCANTH can start to reduce the number of bumps in just 1 treatment.
Before treatment
After first treatment
Images taken from clinical trials. Photos are not representative of all patients.
In clinical trials, patients received between 1 and 4 treatments; 50% of patients achieved complete clearance in just 12 weeks of treatment with YCANTH compared with 15.6% of patients on placebo.
The most common side effects for YCANTH were local skin reactions at the application site, including blistering, pain, itching, scabbing, redness, and discoloration. These reactions are expected and are related to the anticipated blistering caused by YCANTH.
It primarily affects children and is highly contagious. When left untreated, symptoms can last an average of 13 months but could persist for several years, burdening your household and increasing the risk for sibling spread, scarring, and social isolation for your child.
The bumps can present differently in each patient but are typically small, white, or skin-colored, with a dimpled center, and can vary in size from a pinpoint to a small pencil eraser. Occasionally, they can become inflamed or red. In children, the bumps are most commonly seen on their arms, legs, and face and can also form clusters.
It primarily affects children and is highly contagious. When left untreated, symptoms can last an average of 13 months but could persist for several years, burdening your household and increasing the risk for sibling spread, scarring, and social isolation for your child.
The bumps can present differently in each patient but are typically small, white, or skin-colored, with a dimpled center, and can vary in size from a pinpoint to a small pencil eraser. Occasionally, they can become inflamed or red. In children, the bumps are most commonly seen on their arms, legs, and face and can also form clusters.
Data on file. Verrica Pharmaceuticals Inc.
Don’t use products marketed to treat molluscum, a common skin condition. US Food and Drug Administration. Updated June 1, 2023. Accessed July 5, 2023. https://www.fda.gov/consumers/consumer-updates/dont-use-products-marketed-treat-molluscum-common-skin-condition
Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(12):1315-1323.
Eichenfield LF, Sigfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP‐102, a drug‐device combination product containing cantharidin 0.7% (w/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22(2):257-265.
Eichenfield LF, Willson C, McBride M, Davidson M, Burnett P. CAMP-1 and CAMP-2: phase 3, randomized, double-blind, vehicle-controlled, pivotal studies investigating VP-102, a novel drug-device combination containing a topical formulation of cantharidin for the treatment of molluscum contagiosum. Poster presented at: Integrative Dermatology Symposium; October 3, 2019; San Diego, CA.
Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol. 2001;137(10):1357-1360.
Molluscum contagiosum: overview. American Academy of Dermatology Association. Accessed July 5, 2023. https://www.aad.org/public/diseases/a-z/molluscum-contagiosum-overview
Olsen JR, Gallacher J, Finaly AY, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15(2):190-195.
Silverberg NB. Pediatric molluscum: an opdate. Cutis. 2019;104(5):301-305.
Torbeck R, Pan M, DeMoll E, Levitt J. Cantharidin: a comprehensive review of the clinical literature. Dermatol Online J. 2014;20(6).
Verrica Pharmaceuticals announces FDA acceptance of filing of resubmitted NDA for VP-102 for the treatment of molluscum contagiosum. News release. February 27, 2023. Accessed July 5, 2023. https://verrica.com/press_release/fda-accepts-resubmitted-filing-for-vp-102-for-the-treatment-of-molluscum-contagiosum/
YCANTH™. Package insert. Verrica Pharmaceuticals Inc.; 2023.
YCANTH™. Patient information. Verrica Pharmaceuticals Inc.; 2023.
INDICATION:
YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
IMPORTANT SAFETY INFORMATION:
What warnings should I know about YCANTH?
What are the possible side effects of YCANTH?
The most common side effects are local skin side effects at the application site, including blistering, pain, itching, scabbing, redness, discoloration, dryness, swelling, and loss of the outer layer of skin at the application site. These local skin side effects are expected and are related to the anticipated blistering caused by YCANTH.
Do other medications interact with YCANTH?
It is not currently known if any medications interact with YCANTH.
Can I use YCANTH if I’m pregnant?
The potential risk of YCANTH for major birth defects, miscarriage, or maternal or fetal side effects is unknown. Given that YCANTH is applied to the outside of the mother’s skin, use is not expected to result in exposure of YCANTH to unborn babies.
Can I use YCANTH if I’m breastfeeding?
Do not use YCANTH on areas of the mother’s body where YCANTH may come in contact with the breastfeeding child’s mouth or eyes.
What should I do if YCANTH is swallowed?
Taking cantharidin by mouth has resulted in kidney failure, blistering and severe damage to the stomach and intestines, excessive bleeding or clotting, seizures, and weakness or paralysis. Seek medical attention immediately if YCANTH is accidentally ingested.
These are not all the possible side effects of YCANTH. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422). Local skin side effects are expected and should be reported if they are severe.
Please see full Prescribing Information.
INDICATION:
YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
IMPORTANT SAFETY INFORMATION:
What warnings should I know about YCANTH?
